Author: admin

Electric Construction Equipment Market Size, Share, Report, Forecast 2030

“Electric Construction Equipment Market”
Electric Construction Equipment Market by Equipment type, Battery Capacity, Battery Chemistry, Power Output, Application, Propulsion, Electric Tractor Market, Electric Construction & Mining Equipment and Region – Global Forecast to 2030

The global electric construction equipment market size is projected to grow from USD 10.2 billion in 2023 to USD 44.8 billion by 2030, at a CAGR of 23.6% from 2023 to 2030

The market is driven by factors such as – increasing demand to minimize exhaust emissions, operational benefits such as decreased ventilation costs in underground mining & lower operating costs of electric equipment, and growing regulations for low-noise construction machines in residential areas.

The electric dump trucks are expected to hold the largest market share in 2023

Dump trucks mainly find their applications in mining and construction. Dump truck electrification can curb ventilation costs and reduce overall operational costs, benefiting surface and underground operations in mining. Key players like Komatsu Ltd., Caterpillar Inc., and Epiroc AB are prominent in this global market. Electric dump trucks represent a transformative shift in mining, embracing sustainability and stringent regulations. Notable advancements include Komatsu’s hybrid excavator and Sandvik’s battery-electric truck, which minimize emissions and enhance efficiency. Industry giants like BHP Billiton and Caterpillar’s collaboration signifies a collective push toward large-scale electric truck development. These innovations promise reduced emissions, improved efficiency, and substantial cost savings.

Off-highway equipment manufacturers are prioritizing electric dump trucks despite higher initial costs due to long-term savings in fuel and maintenance. With increased battery range and lifespan electric dump trucks are a viable option for longer hauling distances within mine sites. With initiatives like Hitachi Construction Machinery and ABB partnering to develop emission-free dump trucks or Caterpillar Inc.’s first large battery-electric dump truck prototype, the market for electric dump trucks is set to grow at a promising rate.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=129288251

Lithium-Ion Phosphate (LFP) batteries are estimated to dominate the electric construction equipment market.

Lithium iron phosphate (LiFePO4) batteries are gaining traction in the market due to their extended lifespan, efficient charging, and enhanced safety features compared to traditional ones. These batteries offer consistent power delivery, quicker recharging, and a smaller footprint. Additionally, these batteries are more economical than others like NMC or NCA, as they do not use minerals like cobalt or manganese. Automakers are reducing cobalt use due to ethical concerns, favoring LFP technology for its lower manufacturing costs and better charge preservation. Despite their weight, LFPs enable a full 100% charge without battery degradation, making them suitable for various applications, especially those with less critical weight. The LFP batteries also have other advantages over NMC or NCA, like higher resistance to elevated temperatures. Though they require more physical space due to lower energy density, they offer safety benefits and stability, particularly at higher temperatures.

China plays a dominant role in global LiFePO4 battery production, followed by its production of NMC cathodes. Chinese production is expected to continue its significant influence. However, the concentration of LFP cell production in China raises concerns about reliance on China as the major battery source. This generates a need to diversify supply chains.

Considering the advantages offered, such as extended lifespan, resilience at higher temperatures, lower costs, and faster charge rates, LFPs are advantageous for high-performance scenarios and rapid charging.

Americas is anticipated to be the second-largest market in 2023, driven by growing electrification trends.

The Americas region is estimated to be the second-largest market for electric off-highway equipment, with key countries like the US, Canada, Mexico, Brazil, and Argentina contributing significantly. This growth is propelled by stringent environmental measures and upcoming emission regulations, compelling manufacturers to focus on electric and hybrid equipment. Major players such as Caterpillar Inc., Deere & Company, Soletrac Inc., and Dana Limited drive innovation in this domain.

This region’s abundant natural resources, including coal, iron, zinc, copper, cement, lithium, and precious metals, fuel a robust mining industry. The market here is poised to be the second largest globally, driven mainly by the demand for mini-construction equipment like excavators, loaders, and dozers.

The US is expected to lead this market by 2030, reaching an estimated value of USD XX billion. The surge is attributed to increasing demands for electrification in construction, mining, and agriculture vehicles due to emission reduction benefits. Notably, significant investments in electric off-highway equipment, subsystems, and battery advancements by major manufacturers in the US, along with collaborations and funding ventures, are driving growth. For instance, Caterpillar Inc.’s substantial investment in lithium-ion battery development underscores a focus on overcoming conventional battery limitations and propelling the growth of electric equipment in the US.

Key Players

Major players operating in the electric construction equipment market are Caterpillar Inc. (US), Komatsu Ltd. (Japan), Volvo Construction Equipment (Sweden), Hitachi Construction Machinery (Japan), and Deere & Company (US).

Request Free Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=129288251

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/off-highway-electric-vehicle-market-129288251.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Electric Construction Equipment Market Size, Share, Report, Forecast 2030

Big Data Market Size,Trends, Opportunities, Key Players, Growth Factors, Revenue Analysis,and Forecast 2028

“Oracle (US), Microsoft (US), SAP (Germany), IBM (US), and SAS Institute (US) along with startups and SMEs such as Sisense (US), Ataccama (Canada), Imply (US), Centerfield (US), and Datapine (Germany).”
Big Data Market by Offering (Software (Big Data Analytics, Data Mining), Services), Business Function (Marketing & Sales, Finance & Accounting), Data Type (Structured, Semi-structured, Unstructured), Vertical and Region – Global Forecast to 2028

The global big data market is projected to register a CAGR of 12.7% during the forecast period, reaching USD 401.2 billion by 2028 from an estimated USD 220.2 billion in 2023. The growth of big data solutions is propelled by a convergence of factors. These include the ascent of artificial intelligence (AI) and machine learning (ML) in enterprise applications, the increasing demand for data-driven decision-making and the exponential rise in data volume.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1068

By offering, big data consulting services segment to register the largest market share during the forecast period.

Big data consulting services play a pivotal role in guiding businesses through the complexities of implementing and optimizing big data solutions. With a focus on tailored strategies, these services assist companies in harnessing the full potential of their data. The dominance of big data consulting services can be attributed to the increasing awareness among businesses about the strategic importance of data-driven decision-making. Current market trends reflect a growing demand for personalized, industry-specific consulting, as organizations seek expertise to navigate evolving technologies and extract maximum value from their data assets.

By business function, operations segment is poised for the fastest growth rate during the forecast period.

The operations segment in the big data market involves optimizing internal processes, enhancing efficiency, and ensuring seamless workflows. This business function is set to register the fastest growth due to a heightened focus on operational excellence, cost reduction, and increased demand for real-time analytics in supply chain management. The integration of big data with operations business function indicate a rising adoption of predictive maintenance, inventory optimization, and demand forecasting, leveraging big data to streamline operations and gain a competitive edge in the ever-evolving business landscape.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=1068

Unique Features in the Big Data Market

By allowing jobs to be executed concurrently across several nodes or processors, parallel processing capabilities maximise the speed and effectiveness of data processing.

Big Data systems improve fault tolerance and performance by storing and processing data across several servers or nodes by utilising distributed computing architectures.

Big Data systems with in-memory processing capabilities may store and process data in RAM, which speeds up analytics processing and data retrieval as compared to conventional disk-based systems.

NoSQL databases are frequently used in Big Data solutions because they provide flexibility in managing unstructured and semi-structured data and enable horizontal scaling for enhanced performance.

In Big Data contexts, robust security measures that address privacy concerns and safeguard sensitive data include authentication, authorization, and encryption.

Major Highlights of the Big Data Market

The rising amount, velocity, and variety of data generated by organisations has led to a considerable growth in the global big data market.

Large datasets may now be processed, stored, and analysed using scalable and adaptable infrastructure thanks to cloud-based Big Data solutions. Major cloud providers now provide Big Data services.

Nowadays, businesses are putting a lot of emphasis on real-time data processing since it enables them to evaluate and respond to data almost instantly, supporting applications in fields like customer service, IoT, and fraud detection.

The incorporation of Internet of Things (IoT) data into Big Data platforms has gained popularity, allowing enterprises to extract valuable insights from the copious amounts of data produced by networked devices.

Strong security measures and guaranteeing adherence to data protection laws are more important than ever because of the growing awareness of cybersecurity dangers and privacy issues.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=1068

Top Key Companies in the Big Data Market

Some leading players in the big data market include Oracle (US), Microsoft (US), SAP (Germany), IBM (US), SAS Institute (US), Salesforce (US), AWS (US), Teradata (US), Google (US), Accenture (Ireland), Alteryx (US), Cloudera (US), TIBCO (US), Informatica (US), Wipro (India), HPE (US), Qlik (US), Splunk (US), and VMWare (US). These players have adopted various organic and inorganic growth strategies, such as new product launches, partnerships and collaborations, and mergers and acquisitions, to expand their presence in the big data market.

Oracle

Oracle is one of the prominent players in the big data market, offering comprehensive solutions that empower organizations to harness the vast potential of massive datasets. With a robust suite of products and services, Oracle seamlessly integrates traditional and emerging technologies to provide scalable, high-performance solutions. Its Big Data Appliance and Oracle Exadata Database Machine are pivotal in handling the velocity, volume, and variety of big data. Oracle’s approach emphasizes the entire data lifecycle, from ingestion and storage to processing and analysis. The platform supports various data types, including structured and unstructured data, enabling businesses to derive valuable insights from diverse sources. Advanced analytics tools and machine learning capabilities further enhance Oracle’s big data offerings, facilitating predictive modeling and data-driven decision-making. The platform’s flexibility accommodates both on-premises and cloud deployment models, ensuring adaptability to varying business needs.

Microsoft

Microsoft offers a comprehensive suite of solutions that cater to the evolving needs of businesses in today’s data-driven landscape. With Azure, its cloud computing platform, Microsoft provides a robust and scalable infrastructure for handling large volumes of data. Azure’s data services, including Azure Data Lake Storage and Azure SQL Data Warehouse, empower organizations to store, process, and analyze massive datasets efficiently. Powerful tools like Azure HDInsight integrate seamlessly with popular open-source big data frameworks like Hadoop and Spark, facilitating data processing and analytics at scale. Microsoft’s commitment to open-source technologies ensures compatibility and flexibility for users seeking diverse solutions. Additionally, Azure Machine Learning enables businesses to harness the potential of machine learning algorithms, making predictive analytics and data-driven insights more accessible. Microsoft’s holistic approach extends to user-friendly interfaces such as Power BI, which allows for intuitive data visualization and reporting.

IBM

IBM leverages its extensive expertise and cutting-edge technologies to empower organizations in extracting valuable insights from vast and complex datasets. With a comprehensive suite of big data solutions, IBM offers a robust platform that enables businesses to manage, analyze, and derive actionable intelligence from their data. The company’s flagship big data platform, IBM BigInsights, incorporates advanced analytics, machine learning, and data processing capabilities, providing a scalable and efficient solution for handling massive datasets. IBM’s commitment to open-source technologies, such as Apache Hadoop and Spark, underscores its dedication to fostering innovation and collaboration within the big data community. Moreover, IBM’s cloud-based offerings, like IBM Cloud Pak for Data, facilitate seamless integration and accessibility, allowing enterprises to harness the power of big data irrespective of their infrastructure. With a rich history in data management and analytics, IBM continues to push the boundaries of what’s possible in the big data landscape.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/big-data-market-1068.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Big Data Market Size,Trends, Opportunities, Key Players, Growth Factors, Revenue Analysis,and Forecast 2028

Systemic Sclerosis-associated Interstitial Lung Disease Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | MERCK, GSK, Genentech

“Systemic Sclerosis-associated Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Systemic Sclerosis-associated Interstitial Lung Disease, historical and forecasted epidemiology as well as the Systemic Sclerosis-associated Interstitial Lung Disease market trends in the 7MM.

DelveInsight’s “Systemic Sclerosis-associated Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Systemic Sclerosis-associated Interstitial Lung Disease, historical and forecasted epidemiology as well as the Systemic Sclerosis-associated Interstitial Lung Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Systemic Sclerosis-associated Interstitial Lung Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Systemic Sclerosis-associated Interstitial Lung Disease Market Forecast

 

Some of the key facts of the Systemic Sclerosis-associated Interstitial Lung Disease Market Report: 

  • The Systemic Sclerosis-associated Interstitial Lung Disease market size was valued approximately USD 750 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In February 2023, GSK plc (LSE/NYSE: GSK) has disclosed that the US Food and Drug Administration (FDA) has bestowed Orphan Drug Designation (ODD) upon Benlysta (belimumab), a monoclonal antibody that inhibits B-cells. This designation is for the potential treatment of systemic sclerosis. GSK intends to commence a phase II/III trial evaluating the use of belimumab for systemic sclerosis-associated interstitial lung disease (SSc-ILD) during the first half of 2023.
  • The existing pipeline for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) includes prospective drugs with the potential to impact market dynamics. PRA023, Belimumab (GSK1550188), Vixarelimab (KPL-716), and several others are among the prominently featured drugs for this indication.
  • The collective diagnosed prevalent population of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in the 7MM reached approximately 53,178 in 2022. There is an anticipated substantial increase in these cases at a notable Compound Annual Growth Rate (CAGR) over the study period from 2019 to 2032.
  • Within the European countries, the United Kingdom exhibited the highest number of diagnosed prevalent cases of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), totaling around 4,269 cases in 2022. Italy and France followed closely in the same year. In contrast, Germany had the lowest diagnosed prevalent population in that specific year.
  • According to the analysis, it has been noted that the age group with the highest number of diagnosed patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) is 65 and above, while the lowest incidence is observed in the 0-18 age group.
  • Key Systemic Sclerosis-associated Interstitial Lung Disease Companies: Prometheus Biosciences, Inc., MERCK, GlaxoSmithKline, Genentech, Inc., Acceleron, Boehringer Ingelheim, Actelion, Hôpital Claude-Huriez, Changchun GeneScience Pharmaceutical, and others
  • Key Systemic Sclerosis-associated Interstitial Lung Disease Therapies: PRA023, Belimumab, Vixarelimab, MK-2225 (ACE-1334), Nintedanib, bosentan, Belimumab, Cyclophosphamide, GenSci048, and others
  • The Systemic Sclerosis-associated Interstitial Lung Disease epidemiology based on gender analyzed that females are more likely to get affected by SSc-ILD in comparison to male
  • The Systemic Sclerosis-associated Interstitial Lung Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Systemic Sclerosis-associated Interstitial Lung Disease pipeline products will significantly revolutionize the Systemic Sclerosis-associated Interstitial Lung Disease market dynamics.

 

Systemic Sclerosis-associated Interstitial Lung Disease Overview

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) is a complication associated with systemic sclerosis (SSc), also known as scleroderma. Systemic sclerosis is a chronic autoimmune connective tissue disorder characterized by abnormal immune system activity, vascular problems, and excessive collagen deposition in the skin and other organs.

 

Get a Free sample for the Systemic Sclerosis-associated Interstitial Lung Disease Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild-market

 

Systemic Sclerosis-associated Interstitial Lung Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Systemic Sclerosis-associated Interstitial Lung Disease Epidemiology Segmentation:

The Systemic Sclerosis-associated Interstitial Lung Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Systemic Sclerosis-associated Interstitial Lung Disease
  • Prevalent Cases of Systemic Sclerosis-associated Interstitial Lung Disease by severity
  • Gender-specific Prevalence of Systemic Sclerosis-associated Interstitial Lung Disease
  • Diagnosed Cases of Episodic and Chronic Systemic Sclerosis-associated Interstitial Lung Disease

 

Download the report to understand which factors are driving Systemic Sclerosis-associated Interstitial Lung Disease epidemiology trends @ Systemic Sclerosis-associated Interstitial Lung Disease Epidemiology Forecast

 

Systemic Sclerosis-associated Interstitial Lung Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Systemic Sclerosis-associated Interstitial Lung Disease market or expected to get launched during the study period. The analysis covers Systemic Sclerosis-associated Interstitial Lung Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Systemic Sclerosis-associated Interstitial Lung Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Systemic Sclerosis-associated Interstitial Lung Disease Therapies and Key Companies

  • PRA023: Prometheus Biosciences, Inc./ MERCK
  • Belimumab: GlaxoSmithKline
  • Vixarelimab: Genentech, Inc.
  • MK-2225 (ACE-1334): Acceleron/ MERCK
  • Nintedanib: Boehringer Ingelheim
  • bosentan: Actelion
  • Belimumab: GlaxoSmithKline
  • Cyclophosphamide: Hôpital Claude-Huriez
  • GenSci048: Changchun GeneScience Pharmaceutical

 

Discover more about therapies set to grab major Systemic Sclerosis-associated Interstitial Lung Disease market share @ Systemic Sclerosis-associated Interstitial Lung Disease Treatment Landscape

 

Systemic Sclerosis-associated Interstitial Lung Disease Market Strengths

  • The shortfall of therapeutic candidates in the emerging pipeline as well as in the market can give an advantage to emerging therapy to gain huge market share with lesser competition.

 

Systemic Sclerosis-associated Interstitial Lung Disease Market Opportunities

  • The scarcity of approved treatment options offers a great opportunity for the investment and development of novel therapies.

 

Scope of the Systemic Sclerosis-associated Interstitial Lung Disease Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Systemic Sclerosis-associated Interstitial Lung Disease Companies: Prometheus Biosciences, Inc., MERCK, GlaxoSmithKline, Genentech, Inc., Acceleron, Boehringer Ingelheim, Actelion, Hôpital Claude-Huriez, Changchun GeneScience Pharmaceutical, and others
  • Key Systemic Sclerosis-associated Interstitial Lung Disease Therapies: PRA023, Belimumab, Vixarelimab, MK-2225 (ACE-1334), Nintedanib, bosentan, Belimumab, Cyclophosphamide, GenSci048, and others
  • Systemic Sclerosis-associated Interstitial Lung Disease Therapeutic Assessment: Systemic Sclerosis-associated Interstitial Lung Disease current marketed and Systemic Sclerosis-associated Interstitial Lung Disease emerging therapies
  • Systemic Sclerosis-associated Interstitial Lung Disease Market Dynamics: Systemic Sclerosis-associated Interstitial Lung Disease market drivers and Systemic Sclerosis-associated Interstitial Lung Disease market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Systemic Sclerosis-associated Interstitial Lung Disease Unmet Needs, KOL’s views, Analyst’s views, Systemic Sclerosis-associated Interstitial Lung Disease Market Access and Reimbursement 

 

To know more about Systemic Sclerosis-associated Interstitial Lung Disease companies working in the treatment market, visit @ Systemic Sclerosis-associated Interstitial Lung Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Systemic Sclerosis-associated Interstitial Lung Disease Market Report Introduction

2. Executive Summary for Systemic Sclerosis-associated Interstitial Lung Disease

3. SWOT analysis of Systemic Sclerosis-associated Interstitial Lung Disease

4. Systemic Sclerosis-associated Interstitial Lung Disease Patient Share (%) Overview at a Glance

5. Systemic Sclerosis-associated Interstitial Lung Disease Market Overview at a Glance

6. Systemic Sclerosis-associated Interstitial Lung Disease Disease Background and Overview

7. Systemic Sclerosis-associated Interstitial Lung Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Systemic Sclerosis-associated Interstitial Lung Disease 

9. Systemic Sclerosis-associated Interstitial Lung Disease Current Treatment and Medical Practices

10. Systemic Sclerosis-associated Interstitial Lung Disease Unmet Needs

11. Systemic Sclerosis-associated Interstitial Lung Disease Emerging Therapies

12. Systemic Sclerosis-associated Interstitial Lung Disease Market Outlook

13. Country-Wise Systemic Sclerosis-associated Interstitial Lung Disease Market Analysis (2019–2032)

14. Systemic Sclerosis-associated Interstitial Lung Disease Market Access and Reimbursement of Therapies

15. Systemic Sclerosis-associated Interstitial Lung Disease Market Drivers

16. Systemic Sclerosis-associated Interstitial Lung Disease Market Barriers

17.  Systemic Sclerosis-associated Interstitial Lung Disease Appendix

18. Systemic Sclerosis-associated Interstitial Lung Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Systemic Sclerosis-associated Interstitial Lung Disease Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | MERCK, GSK, Genentech

Asthma Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca

“Asthma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Asthma, historical and forecasted epidemiology as well as the Asthma market trends in the 7MM.

DelveInsight’s “Asthma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Asthma, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Asthma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Asthma Market Forecast

 

Some of the key facts of the Asthma Market Report: 

  • In 2022, the asthma market size in the United States contributed to a total of USD 13.3 billion within the 7MM (Seven Major Markets). The forecast indicates an anticipated growth in the asthma market size across the 7MM during the forecast period, driven by the potential introduction of new therapies.
  • The market size in the United Kingdom reached USD 1,295 million in 2022, marking the highest figure, whereas Spain reported the lowest market size with an estimated share of around USD 464 million in the same year.
  • The patent protection for the syringe formulation of XOLAIR in the United States and Europe is anticipated to conclude between 2024 and 2025. Currently, there is no presence of generic competition in either the United States or the European Union.
  • CINQAIR possesses biological exclusivity in the United States until 2028 and is granted regulatory exclusivity in Europe until 2026.
  • The collective number of diagnosed prevalent cases of asthma in the 7MM was approximated to be 55 million cases in 2022. Among these cases, the adult population had the highest diagnosed prevalent cases, and this number is anticipated to rise by 2032.
  • As per the World Health Organization (WHO) in 2022, asthma represents a significant non-communicable disease impacting individuals across various age groups, with children being particularly susceptible. It stands as the most prevalent chronic ailment among children. In 2019, approximately 262 million individuals were affected by asthma, resulting in 455,000 deaths.
  • In February 2022, Honeywell disclosed a business collaboration with AstraZeneca aimed at the development and introduction of advanced respiratory inhalers. These inhalers are designed to utilize propellants with near-zero global warming potential (GWP) for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
  • Key Asthma Companies: GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Sterna Biologicals, Cipla Ltd., Global United Pharmaceutical Corporation, Ossium Health, Inc., SinoMab BioScience Ltd, Chiesi Farmaceutici S.p.A., Amgen, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others
  • Key Asthma Therapies: GSK3511294 (Depemokimab), Masitinib (AB07105), PT010, Dexpramipexole Dihydrochloride, ARS 1, MEDI3506 (tozorakimab), AZD1402 (PRS-060), Atuliflapon (AZD5718), Amlitelimab, Rilzabrutinib, BOXABAN (Ifetroban), RG6341 (GDC-6599), CBP-201, AVTX-002 (Quisovalimab), MRx-4DP0004, SB010, and others
  • The Asthma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Asthma pipeline products will significantly revolutionize the Asthma market dynamics.

 

Asthma Overview

Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. These symptoms often occur in response to triggers such as allergens, irritants, exercise, or respiratory infections.

 

Get a Free sample for the Asthma Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/asthma-market

 

Asthma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Asthma Epidemiology Segmentation:

The Asthma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Asthma
  • Prevalent Cases of Asthma by severity
  • Gender-specific Prevalence of Asthma
  • Diagnosed Cases of Episodic and Chronic Asthma

 

Download the report to understand which factors are driving Asthma epidemiology trends @ Asthma Epidemiology Forecast

 

Asthma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Asthma market or expected to get launched during the study period. The analysis covers Asthma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Asthma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Asthma Therapies and Key Companies

  • GSK3511294 (Depemokimab): GlaxoSmithKline
  • Masitinib (AB07105): AB Science
  • PT010: AstraZeneca
  • Dexpramipexole Dihydrochloride: Areteia Therapeutics
  • ARS 1: ARS Pharmaceuticals, Inc.
  • MEDI3506 (tozorakimab): AstraZeneca
  • AZD1402 (PRS-060): Pieris Pharma/AstraZeneca
  • Atuliflapon (AZD5718): AstraZeneca
  • Amlitelimab: Sanofi
  • Rilzabrutinib: Sanofi
  • BOXABAN (Ifetroban): Cumberland Pharmaceuticals
  • RG6341 (GDC-6599): Genentech Research/Roche
  • CBP-201: Suzhou Connect Biopharmaceuticals
  • AVTX-002 (Quisovalimab): Avalo Therapeutics
  • MRx-4DP0004: 4D Pharma plc
  • SB010: Sterna Biologicals

 

Discover more about therapies set to grab major Asthma market share @ Asthma Treatment Landscape

 

Asthma Market Strengths

  • Robust pipeline of drugs targeting a variety of different and more effective pathogenic mechanisms in asthma.

 

Asthma Market Opportunities

  • Availability of varied formulation types and convenient dosing schedules for more effective treatment.

 

Scope of the Asthma Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Asthma Companies: GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Sterna Biologicals, Cipla Ltd., Global United Pharmaceutical Corporation, Ossium Health, Inc., SinoMab BioScience Ltd, Chiesi Farmaceutici S.p.A., Amgen, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others
  • Key Asthma Therapies: GSK3511294 (Depemokimab), Masitinib (AB07105), PT010, Dexpramipexole Dihydrochloride, ARS 1, MEDI3506 (tozorakimab), AZD1402 (PRS-060), Atuliflapon (AZD5718), Amlitelimab, Rilzabrutinib, BOXABAN (Ifetroban), RG6341 (GDC-6599), CBP-201, AVTX-002 (Quisovalimab), MRx-4DP0004, SB010, and others
  • Asthma Therapeutic Assessment: Asthma current marketed and Asthma emerging therapies
  • Asthma Market Dynamics: Asthma market drivers and Asthma market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Asthma Unmet Needs, KOL’s views, Analyst’s views, Asthma Market Access and Reimbursement 

 

To know more about Asthma companies working in the treatment market, visit @ Asthma Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Asthma Market Report Introduction

2. Executive Summary for Asthma

3. SWOT analysis of Asthma

4. Asthma Patient Share (%) Overview at a Glance

5. Asthma Market Overview at a Glance

6. Asthma Disease Background and Overview

7. Asthma Epidemiology and Patient Population

8. Country-Specific Patient Population of Asthma 

9. Asthma Current Treatment and Medical Practices

10. Asthma Unmet Needs

11. Asthma Emerging Therapies

12. Asthma Market Outlook

13. Country-Wise Asthma Market Analysis (2019–2032)

14. Asthma Market Access and Reimbursement of Therapies

15. Asthma Market Drivers

16. Asthma Market Barriers

17.  Asthma Appendix

18. Asthma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Asthma Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca

A Renowned Rock and Metal Troubadour, Kevin Goocher Delivers a Moving and Passionate Ode to Country and Southern Rock Music

A Renowned Rock and Metal Troubadour, Kevin Goocher Delivers a Moving and Passionate Ode to Country and Southern Rock Music
A renowned Rock and Metal troubadour, Kevin Goocher delivers a moving and passionate ode to Country and Southern Rock music

In the eclectic landscape of music, Kevin Goocher has been a force to be reckoned with, dominating the stages worldwide with his dynamic presence in the rock and metal realms. Now, with a stunning turn of events, Goocher is ready to enchant audiences in a different cadence, exploring the heart and soul of country and southern rock.

The much-anticipated EP, “My Friends Call Me Gooch,” is slated for release on January 25, 2024, marking a significant departure from Goocher’s rock and metal legacy. Produced by the seasoned Wyn Davis, known for his work with iconic names like Guns & Roses, Foreigner, and Van Morrison, and co-produced by Steve Ornest, the EP promises a sonic journey enriched with authenticity and passion.

Each track is a testament to Goocher’s musical evolution and a celebration of his return to the genres that first ignited his love for music. All songs on the EP are a collaborative creation, bearing the signature touch of Kevin Goocher and his wife, Melanie Goocher.

The memorable EP boasts a stellar lineup of musical virtuosos, including Aaron Sterling on drums (Taylor Swift, John Mayer, Harry Styles), Dane Bryant on Keyboards/Piano (Olivia Newton John, Dolly Parton), Chris Condon and Shaun Richardson on Guitars (Billy Ray Cyrus, Michael Martin Murphy, Jesse James Decker), Russ Pahl on Steel Guitar (Carrie Underwood, Blake Shelton, Luke Bryan), and Ted Pecchio on Bass Guitar (Doyle Bramhall 2nd, Derek Trucks Band). The harmonious backdrop is further elevated by the enchanting backup vocals of Annie Bosko.

Goocher’s venture into country and southern rock is not a mere departure; it’s a earnest return to the music that has been the silent soundtrack to his life. The EP is a carefully curated collection of songs that resonate with genuine emotions, showcasing a side of Kevin Goocher that goes beyond the electric guitar riffs and pulsating drums.

“My Friends Call Me Gooch” promises to present a narrative, a musical odyssey that reintroduces Kevin Goocher as a songsmith in the realms of country and southern rock. With this release, “Gooch” extends an invitation to his fans and friends to join him on this resonant exploration of his musical roots.

Stream the artist’s new music on Apple Music, Amazon Music, and Spotify! Kevin Goocher invites all music enthusiasts to embark on this soulful journey. The EP not only stands as a testament to Goocher’s versatility but also as a love letter to the genres that shaped his musical soul.

For more information and updates on live shows near you, follow Kevin Goocher at the below links.

ABOUT

Kevin Goocher, a name synonymous with the thunderous beats of rock and metal, unveils a soulful chapter of his musical journey with the release of his upcoming EP, “My Friends Call Me Gooch.” Best known for his global exploits with bands Omen and Of Gods & Monsters, Kevin Goocher takes a delightful detour back to his roots, serenading audiences with the raw and honest melodies of country and southern rock.

LINKS

Facebook: http://www.facebook.com/kevingoochermusic

Spotify: https://open.spotify.com/artist/6F742HSrbtUno76yyNb1YN?si=W9WrfYGATXGhC_lBTuihhA

TikTok: https://www.tiktok.com/@kevingoochermusic?_t=8izG66VBvWl&_r=1

Website: www.kevingoocher.com

Media Contact
Company Name: HellAPhonic Music
Contact Person: Kevin Goocher
Email: Send Email
Phone: 800-983-1362
City: Los Angeles
State: California
Country: United States
Website: https://www.facebook.com/kevingoochermusic

Achondroplasia Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies and Competitive Intelligence by DelveInsight | BridgeBio, QED Therapeutics , Ribomic, Sanofi, Ascendis Pharma

“Achondroplasia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Achondroplasia, historical and forecasted epidemiology as well as the Achondroplasia market trends in the 7MM.

DelveInsight’s “Achondroplasia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Achondroplasia, historical and forecasted epidemiology as well as the Achondroplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Achondroplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Achondroplasia Market Forecast

 

Some of the key facts of the Achondroplasia Market Report: 

  • The Achondroplasia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In January 2022, Ascendis Pharma A/S announced that the European Commission (EC) granted marketing authorization for TransCon hGH. This approval allows for the once-weekly subcutaneous injection of TransCon hGH as a treatment for children and adolescents aged 3 to 18 years experiencing growth failure due to inadequate secretion of endogenous growth hormone, also known as growth hormone deficiency (GHD). TransCon hGH is a prodrug of somatropin, offering sustained release of unmodified somatropin (hGH) at predictable therapeutic levels in the body. The EC’s decision is grounded in clinical findings presented in the Marketing Authorization Application (MAA), incorporating data from Ascendis Pharma’s Phase III heiGHt, fliGHt, and enliGHten Trials. These trials collectively involved over 300 pediatric patients diagnosed with GHD, and the authorization also considered information from a non-clinical safety program.
  • In April 2022, RIBOMIC, Inc. submitted an Investigational New Drug Application (IND) for an observational study involving the drug RBM-007. This drug has demonstrated potent effects in restricting excessive interactions between fibroblast growth factors, recognized contributors to achondroplasia. The submission was made to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Concurrently, TransCon hGH is undergoing development for pediatric Growth Hormone Deficiency (GHD) in Japan, and BridgeBio has reported positive Phase II results for Infigratinib. These advancements are anticipated to enhance the long-term prospects in the treatment landscape for achondroplasia. Consequently, the global medical community is adjusting its Research and Development (R&D) priorities, placing a significant emphasis on exploring the future development of therapeutic drug candidates for achondroplasia. This shift aims to cultivate a potential revenue ecosystem that will significantly drive research in the future.
  • As stated by Benjamin et al., achondroplasia is an autosomal dominant genetic disorder, with the majority of frequency estimates ranging between 1 in 25,000 and 1 in 35,000 live births. However, it is suggested that the actual frequency might be slightly elevated.
  • As per information from NORD, Achondroplasia arises due to an independent genetic mutation in approximately 80% of individuals, while the remaining 20% inherit it from a parent.
  • Key Achondroplasia Companies: BridgeBio/ QED Therapeutics , Ribomic Inc, Sanofi, Changchun GeneScience Pharma, Ascendis Pharma A/S, QED Therapeutics, Inc, BioMarin Pharmaceuticals, BioMarin Pharmaceutical, and others
  • Key Achondroplasia Therapies: Infigratinib, RBM-007, SAR-442501, Recombinant human growth hormone, Infigratinib, TransCon CNP, Infigratinib, vosoritide, BMN 111, and others
  • The Achondroplasia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Achondroplasia pipeline products will significantly revolutionize the Achondroplasia market dynamics.

 

Achondroplasia Overview

Achondroplasia is a genetic disorder characterized by short stature and distinct physical features. It is the most common form of short-limbed dwarfism and results from a mutation in the FGFR3 gene, which plays a crucial role in the development of bones.

 

Get a Free sample for the Achondroplasia Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/achondroplasia-market

 

Achondroplasia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Achondroplasia Epidemiology Segmentation:

The Achondroplasia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Achondroplasia
  • Prevalent Cases of Achondroplasia by severity
  • Gender-specific Prevalence of Achondroplasia
  • Diagnosed Cases of Episodic and Chronic Achondroplasia

 

Download the report to understand which factors are driving Achondroplasia epidemiology trends @ Achondroplasia Epidemiology Forecast

 

Achondroplasia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Achondroplasia market or expected to get launched during the study period. The analysis covers Achondroplasia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Achondroplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Achondroplasia Therapies and Key Companies

  • Infigratinib: BridgeBio/ QED Therapeutics
  • RBM-007: Ribomic Inc
  • Sanofi: SAR-442501
  • Recombinant human growth hormone: Changchun GeneScience Pharma
  • Infigratinib: QED Therapeutics, Inc.
  • TransCon CNP: Ascendis Pharma A/S
  • Infigratinib: QED Therapeutics, Inc
  • vosoritide: BioMarin Pharmaceuticals
  • BMN 111: BioMarin Pharmaceutical

 

Discover more about therapies set to grab major Achondroplasia market share @ Achondroplasia Treatment Landscape

 

Scope of the Achondroplasia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Achondroplasia Companies: BridgeBio/ QED Therapeutics , Ribomic Inc, Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., Ascendis Pharma A/S, QED Therapeutics, Inc, BioMarin Pharmaceuticals, BioMarin Pharmaceutical, and others
  • Key Achondroplasia Therapies: Infigratinib, RBM-007, SAR-442501, Recombinant human growth hormone, Infigratinib, TransCon CNP, Infigratinib, vosoritide, BMN 111, and others
  • Achondroplasia Therapeutic Assessment: Achondroplasia current marketed and Achondroplasia emerging therapies
  • Achondroplasia Market Dynamics: Achondroplasia market drivers and Achondroplasia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Achondroplasia Unmet Needs, KOL’s views, Analyst’s views, Achondroplasia Market Access and Reimbursement 

 

To know more about Achondroplasia companies working in the treatment market, visit @ Achondroplasia Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Achondroplasia Market Report Introduction

2. Executive Summary for Achondroplasia

3. SWOT analysis of Achondroplasia

4. Achondroplasia Patient Share (%) Overview at a Glance

5. Achondroplasia Market Overview at a Glance

6. Achondroplasia Disease Background and Overview

7. Achondroplasia Epidemiology and Patient Population

8. Country-Specific Patient Population of Achondroplasia 

9. Achondroplasia Current Treatment and Medical Practices

10. Achondroplasia Unmet Needs

11. Achondroplasia Emerging Therapies

12. Achondroplasia Market Outlook

13. Country-Wise Achondroplasia Market Analysis (2019–2032)

14. Achondroplasia Market Access and Reimbursement of Therapies

15. Achondroplasia Market Drivers

16. Achondroplasia Market Barriers

17.  Achondroplasia Appendix

18. Achondroplasia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Achondroplasia Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies and Competitive Intelligence by DelveInsight | BridgeBio, QED Therapeutics , Ribomic, Sanofi, Ascendis Pharma

Chip Pearce Collector Car Auctions Announces Public Auction of Rare Kershaw Estate Collection

Chip Pearce Collector Car Auctions Announces Public Auction of Rare Kershaw Estate Collection

Chip Pearce Collector Car Auctions Offers Rare Vintage Automobiles, Trains, and Collectibles from the Estate of Royce G. Kershaw Jr.
Chip Pearce Collector Car Auctions Offers Rare Vintage Automobiles, Trains, and Collectibles from the Estate of Royce G. Kershaw Jr.

Chip Pearce Collector Car Auctions and AuctionbyPearce are set to host a public auction featuring a unique collection of vintage automobiles, trains, and collectibles. This significant event showcases the estate of the late Royce G. Kershaw Jr., offering a rare glimpse into a hidden treasure trove of automotive and rail history.

The Kershaw Family Legacy

The Kershaw name has been synonymous with the railroad industry in Montgomery, Alabama, since 1924. Royce Kershaw Sr. established his company to build and service railroad tracks, later expanding into the development of machines for track maintenance.

The success of this venture not only solidified the Kershaw family’s legacy in Alabama’s industrial history but also fueled a lifelong passion for collecting vintage automobiles and trains.

Royce Kershaw Jr. inherited this passion and expanded the collection, preserving and celebrating the history of each piece. The collection, carefully curated over decades, reflects the evolution of the automotive and railroad industries, marking significant milestones in engineering and design.

The Kershaw collection is not just a testament to the family’s business acumen but also a reflection of their personal journey and evolution as collectors and preservers of history. Each item in the collection has its story, from early Ford Model Ts to elegant Lincolns, showcasing the breadth and depth of their interests.

Discovery of the Collection

In a discovery that captivated the collector car community, 40 vintage automobiles were found in an old, dusty industrial warehouse in Montgomery. This incredible find was out of sight for many years, hidden away from the public eye and preserving a significant part of automotive history.

This collection gained national attention when Richard Rawlings of Gas Monkey Garage featured the estate in a 2022 broadcast on his YouTube channel, which garnered almost 2 million views. Rawlings’ visit and subsequent attempt to purchase the entire collection underscore the collection’s extraordinary nature.

The warehouse, a time capsule of sorts, housed a diverse array of vehicles. Among them were rare finds like a Glenn Pray-designed executive cruiser, an aircraft aluminum RV crafted by Mr. Kershaw, and a (very RARE) 1971 De Tomaso Pantera, an Italian-designed and built sports car with an American Ford racing engine that was one of the first delivered to the United States.

Hidden away for over four decades, these cars offer a window into a bygone era, a tangible connection to the past that is rarely found in such pristine conditions.

Auction Highlights

The upcoming auction by Chip Pearce Collector Car Auctions showcases an impressive range of vintage automobiles and trains, each with its own unique history and appeal. Among the collection’s highlights is a 1959 Cadillac 59 Fleetwood limousine. This particular limousine has the distinction of being used by five former Alabama Governors, including the notable George Wallace. Its historical connections make it a centerpiece of the auction. “This car features the tallest fins of the big fin era of the 50’s and 60’s” according to the auctioneer, Chip Pearce. “The car still has cigar and cigarette burns in the original back seat. Who knows how many important businessmen and dignitaries have ridden in the car over the years”.

Another remarkable item is a rare 1913 Baldwin 2-6-0 Mogul Steam Locomotive & Tender, which holds a special connection to the family of the legendary country music singer Hank Williams. The locomotive, believed to have been operated by Hank Williams’ father, represents a distinct piece of both Alabama’s industrial and cultural history.

“Every car enthusiast dreams of finding a rare car hidden away in a dusty old warehouse or barn”. Well, this is the ultimate barn find, says Chip Pearce! How about more than 40 unique and rare vehicles stored away in a dusty old industrial warehouse. This is an auction you don’t want to miss”

This auction is characterized by its “Absolute Auction” format, where every item, including those valued over $100,000, will start at a bid of $1.00 with no minimum reserve. This approach ensures that each item will find a new owner, making this event a true opportunity for collectors and enthusiasts to acquire a piece of history.

The expertise of Chip Pearce Collector Car Auctions

Larry “Chip” Pearce, the driving force behind Chip Pearce Collector Car Auctions, brings unparalleled expertise to the field of collector cars.

With a career spanning over four decades, Chip has developed a reputation for his profound knowledge and passion for vintage automobiles. His skill in both restoration and appraisal has made him a sought-after figure in the collector car world. Chip’s ability to tell the story behind each vehicle adds a unique dimension to the auctions, making them not only a sale of cars but a celebration of their histories.

AuctionByPearce, under Chip’s leadership, has conducted numerous successful auctions across the United States, dealing with a wide range of significant assets. The firm’s proficiency in handling collector cars, in particular, has positioned it as a leader in this niche market.

The Auction Event

The auction will take place online, allowing global participation, with the items located in an industrial warehouse near downtown Montgomery, Alabama. The auction’s online nature broadens its reach, inviting international bids and increasing the event’s significance in the collector car and train communities.

To accommodate interested buyers, in-person open house dates are scheduled, offering a rare opportunity to view these historic items up close. These viewings allow potential bidders to appreciate the condition and details of each item, adding a tangible element to the online auction experience.

For those interested in participating in this rare auction, details and registration information are available at www.AuctionByPearce.com.

About Chip Pearce Collector Car Auctions and AuctionByPearce

With a legacy of over 40 years, AuctionByPearce, and its subsidiary, Chip Pearce Collector Car Auctions, specialize in selling significant assets such as real estate, business assets, vintage automobiles, and more. Chip Pearce, a seasoned collector car expert, appraiser, and auctioneer, leads the firm with a passion for storytelling and a deep understanding of the collector car market.

For more information and to register for the auction, visit www.AuctionByPearce.com or contact Chip Pearce at chip@auctionbypearce.com

 

Media Contact
Company Name: Chip Pearce Collector Car Auctions
Contact Person: Larry “Chip” Pearce, President
Email: Send Email
City: Montgomery
State: Alabama
Country: United States
Website: www.AuctionByPearce.com

EVITP Supports SkillFusion’s EDT Training And Certification Program For Non-Electrical Professionals Operating And Maintaining EV Charging Stations

“EVITP is the known leader in providing qualified electricians with the appropriate training and certifications to install and maintain EVSE infrastructure. The SkillFusion EDT program expands the effort to support the EV industry with intentional focus and commitment to recognizing the difference between non-electrician and electrical roles”

January 17, 2024 – Detroit, MI – SkillFusion, a cutting-edge software platform for electric vehicle service equipment (EVSE) operations and maintenance (O&M) providers, has been recognized by the Electric Vehicle Infrastructure Training Program (EVITP) for their recently launched EVSE Diagnostic Technician (EDT) training and certification program. EVITP supports SkillFusion’s responsible and market-focused training that clearly delineates non-electrical and electrical work for the safe installation and maintenance of EV charging stations (also known as EVSE), and the program’s connection to career pathways in the electrical industry.

“As the demand for public charging infrastructure continues to grow, we are beginning to see the stress fractures caused by the shortage of technicians prepared and certified to service the non-electrical faults in these chargers, said Bernie Kotlier, the national co-chair of EVITP. “The SkillFusion EDT program takes a responsible approach to training and certifying work-ready individuals to increase charger uptime and reliability across the U.S. and to connect them to career pathways in the electrical industry.”

SkillFusion, which launched its groundbreaking approach to EVSE O&M last year, provides a software platform that supports charger-agnostic skill enhancement and certification for the full spectrum of skills needed to support EV charger operations—including licensed electricians to perform electrical work, and technicians specializing in technical support, networking and communications, cybersecurity, and more. EVITP is a non-profit, volunteer-based organization dedicated to training and certifying qualified electricians in EV infrastructure across the U.S. and Canada. 

“With thousands of public charging stations in the country out of service for non-electrical faults and errors and a shortage of technicians available to service and fix the chargers, the opportunities for EVSE-certified technicians are essentially endless,” said Rue Phillips, Co-founder and President of SkillFusion. “SkillFusion will offer the most comprehensive O&M EVSE training available on the market today and is proud to be recognized by EVITP, the leader in EVSE training and certification.”

As working on EV charging stations can involve exposure to hazardous electrical power, EVITP and SkillFusion share a commitment to clearly distinguish electrical work that can only be safely performed by electricians, and non-electrical work that may be performed by technicians.  

EVITP is the known leader in providing qualified electricians with the appropriate training and certifications to install and maintain EVSE infrastructure. The SkillFusion EDT program expands the effort to support the EV industry with intentional focus and commitment to recognizing the difference between non-electrician and electrical roles.   

“Non-electricians carry out technical work such as networking and communications—which are major causes for EV charger failures. There needs to be a clear understanding and training of what a technician can do vs what an electrician can do within our EV charging infrastructure,” said Phillips.

The new SkillFusion training will provide the industry with a pipeline of certified non-electrical workers (EDTs), critical to the O&M sector of the EV charging industry. They will be connected to a network of service providers, electrical contractors, and career pathways in the electrical industry including work-based learning, pre-apprenticeships, and apprenticeships.

SkillFusion is already curating the most comprehensive set of competency training and credentials for electrical and non-electrical workers specially designed for the EVSE sector. Electricians interested in expanding their expertise to include the non-electrical side of EVSE O&M can access specialized training through SkillFusion and earn that certification as well. Upon completing the training, multi-skilled EVSE-certified electricians can register within SkillFusion’s portal—the largest database of EVSE technicians for hire—and start working with EV charger owners and operators quickly.

Additionally, non-electricians can apply for the new EDT credential while working within a growing, fast paced EV industry.

About SkillFusion

SkillFusion is a first-of-its-kind approach to providing electric vehicle operations and maintenance (O&M) service providers with access to a nation-wide credentialed talent pool for electric vehicle service equipment (EVSE) O&M obligations. Through the company’s cross-sector training platform, SkillFusion is developing the largest talent pipeline of certified electrician and non-electrician workers available to EVSE O&M service providers with the mission of significantly minimizing charging infrastructure downtime and increasing the reliability of the charging network. The platform will substantially increase the availability of certified EVSE workers ensuring that service providers have flawless accessibility to the right trained service person for every job, every single time.

To learn more about SkillFusion, visit www.SkillFusion.com.

About EVITP

The electrical vehicle market continues to expand in North America and it is critical that EVSE equipment be properly installed and maintained to the highest standards of safety and quality. The EVITP non-profit, industry collaborative program, founded in 2011, was designed to provide qualified electricians with the most comprehensive training available in the market today. All EVITP Certified Electricians must pass a certification exam for proof of knowledge and skill.

For more information, visit www.EVITP.org

Media Contact
Company Name: SkillFusion
Contact Person: Caleb Harper
Email: Send Email
Country: United States
Website: https://skillfusion.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: EVITP Supports SkillFusion\’s EDT Training And Certification Program For Non-Electrical Professionals Operating And Maintaining EV Charging Stations

Partisia Blockchain Unveils Revolutionary On-Chain Custody Product, MOCCA, at Davos

MOCCA Unleashed: Partisia Blockchain Redefines Custody with Innovative On-Chain Solution, Paving the Way for Decentralized Financial Inclusion in the Wake of SEC’s Crypto ETF Approvals.

Davos – 17 January, 2024 – Partisia Blockchain, the Swiss innovator committed to delivering cutting-edge, privacy-preserving solutions for fairness and transparency, made a groundbreaking announcement during the World Economic Forum. During the Davos event, Partisia Blockchain launched MOCCA, an on-chain custody product driven by advanced multiparty computation (MPC). MOCCA represents a democratization of access to sophisticated custody solutions, traditionally the domain of large enterprises with substantial budgets. This revelation follows closely on the heels of the Securities and Exchange Commission’s (SEC) recent approval of spot Bitcoin ETFs.

Brian Gallagher, co-founder of Partisia Blockchain, took center stage during his keynote address at a Davos side event to introduce the MOCCA custody product. Powered by Partisia Blockchain’s advanced MPC capabilities, MOCCA leverages decentralization by necessitating approval from two or more parties for every transaction.

In stark contrast to existing custody offerings, MOCCA stands out as a decentralized, open-source solution accessible to all. Users can effortlessly deploy a secure custody environment across multiple parties with just a few clicks. Partisia Blockchain’s fully programmable custody product, equipped with out-of-the-box multichain capability, remains blockchain-agnostic, relying on MPC technology irrespective of protocol support. This ensures unbreakably secure transactions and simplifies the custody of various asset types.

This versatile solution caters to a broad spectrum of use cases, from individuals seeking enhanced security for self-custody of digital assets to more complex scenarios such as firms decentralizing custody, decentralized autonomous organizations (DAOs) pursuing programmable treasury solutions, and exchanges requiring enhanced transparency in fund management.

Gallagher emphasized the solution’s cost efficiency, expedited on-chain deployment timelines, and programmable code capabilities that facilitate advanced smart contract governance. Security takes center stage, with MPC-secured bridges ensuring asset security at rest and during transfers. MOCCA’s off-chain signing feature enables off-chain devices to generate keys and participate in on-chain protocols through clients, making it an ideal choice for institutional clients seeking decentralized custody solutions.

Brian Gallagher stated, “This new solution future-proofs cross-chain custody management, and its launch at Davos aligns perfectly with the evolving regulatory landscape. With the recent SEC approval of spot Bitcoin ETFs and impending approval for spot Ethereum ETFs, the industry demands institutional-grade, blockchain-agnostic custody solutions. Our product balances flexibility with security, allowing firms to bridge assets on Partisia Blockchain or keep them on their preferred chain. This is a timely solution that centers around privacy-preserving financial inclusion, benefiting both traditional and decentralized organizations.”

About Partisia Blockchain:

Partisia Blockchain offers unparalleled opportunities by enabling privacy-preserving, interoperable, and sustainable innovation for fairness and transparency. With 35 years of rigorous research, Partisia Blockchain future-proofs solutions, tackling global challenges by powering fair, secure distribution of benefits. The company prioritizes privacy and confidentiality while bringing accountable, transparent, and decentralized governance.

Learn more: https://partisiablockchain.com/mocca-unveiled-in-davos

Media Contact
Company Name: Byte Group
Contact Person: Media Relations
Email: Send Email
Country: Poland
Website: bakedbyte.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Partisia Blockchain Unveils Revolutionary On-Chain Custody Product, MOCCA, at Davos

Avid Games Launches First-Ever Season Pass for Cards, the Universe and Everything with ‘The Sixth Sense’ as Inaugural Theme

London – 17 January, 2024 – Avid Games announces the launch of the first-ever season pass for their popular mobile game, ‘Cards, the Universe and Everything’ (CUE), with ‘The Sixth Sense’ as the inaugural theme. This new season pass promises to introduce a series of fresh features and updates, offering an enhanced gaming experience in the year ahead.

New Horizons in Mobile Gaming: The season pass features a dual-track system – both free and premium – designed to cater to a diverse player base with varying playstyles.

What Players Can Expect:

  • Dual Reward Tracks: The pass offers varied rewards across free and premium options, catering to all player levels.
  • Engage & Earn: Players can earn season points through weekly challenges and competitive League play.
  • Exclusive Rewards: A variety of rewards including gems, coins, special packs, and Cards await, along with exclusive cosmetics for personalizing the gaming experience.


Extended Seasons for Enhanced Exploration: Seasons in CUE will now be extended, allowing deeper exploration into themes. ‘The Sixth Sense’ kicks off the season, inviting players into a world of the occult, mysticism, and hidden mysteries.

“The Season Pass is all set to add a fresh twist to the game,” said Martin Gardner, Product Director at Avid Games. “We’re eager to see our players’ reactions to this first theme, which will take them on a mystical adventure.”

About Cards, the Universe and Everything:

Praised by Apple as “A game that’s truly one of a kind,” this TCG app merges strategic card battles with an eclectic array of topics. It offers a unique universe where players engage in mind-bending strategy and trivia, featuring unlikely alliances like Shinigami with Cthulhu or a Dachshund with Buzz Aldrin. A must-play for aficionados of quirky facts and intense strategy.

About Avid Games:

Avid Games is the force behind Cards, the Universe and Everything, a Global Top 10 TCG enjoyed by over 3 million players. The Avid Collectibles Engine has powered apps for several major brands, including the NFL, Formula 1, Discovery and the NBA. Learn more at www.avid.games.

For media or partnership inquiries please contact pr@avid.games

Media Contact
Company Name: Virttrade ltd
Contact Person: Duncan Best
Email: Send Email
City: Heathfield
State: East Sussex
Country: United Kingdom
Website: https://www.cardstheuniverseandeverything.com/